<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01532700</url>
  </required_header>
  <id_info>
    <org_study_id>PMH-GSK2110183-CLL001</org_study_id>
    <nct_id>NCT01532700</nct_id>
  </id_info>
  <brief_title>An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, open-label, single institution trial of combination of intravenous (IV)
      ofatumumab and oral GSK2110183 in patients with relapsed or refractory Chronic Lymphocytic
      Leukemia (CLL). Patients must have received at least one prior line of therapy containing
      fludarabine (single-agent or combination therapy). During the initial 6 months Treatment
      Phase, ofatumumab will be administered weekly for 8 doses, then once every 4 week cycle for
      an additional 4 doses (dose and schedule identical to the pivotal phase 2 trial) and
      GSK2110183 will be given daily PO (Treatment Phase). There will be an initial 10 day lead-in
      with GSK2110183 alone prior to initiation of ofatumumab to allow for evaluation of changes in
      cell surface expression due to GSK2110183 and for GSK2110183 pharmacokinetic studies (Lead-in
      Phase). The official Cycle 1 Day 1 will start on the date of first dose of ofatumumab. Cycle
      duration = 4 weeks. Patients will be assessed for safety, disease assessment, response, and
      survival on day 1 of each cycle during the Treatment Phase. A formal review of safety data by
      the Data Safety Monitoring Board (DSMB) after the first 6 patients have completed cycle 1 of
      the Treatment Phase will be performed before continuing accrual. All patients achieving SD,
      PR or CR by the end of the Treatment Phase will proceed to the Maintenance Phase. Patients
      with PD at any time, including by the end of Treatment Phase, will be taken off study. During
      the Maintenance Phase, single-agent GSK2110183 will be administered daily for a maximum of 12
      months (12 cycles). Maximum duration on any study drug is 18 months (18 cycles). During the
      Follow-up Phase, patients will be assessed for safety, disease assessment, response, and
      survival every 3 months through month 36 (year 3), or until subsequent CLL therapy or death,
      whichever comes first. Key indications for study withdrawal are progressive disease,
      intolerable toxicity, or completion of therapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate, as Per the IWCLL 2008 Response Criteria</measure>
    <time_frame>36 months</time_frame>
    <description>IWCLL Response Criteria 2008-Hallek. Complete response (CR): requires peripheral blood lymphocytes &lt; 4 x 109/L, absence of significant lymphadenopathy (&gt;1.5cm), no organomegaly, normal CBC, bone marrow must be at least normocellular; Complete Remission with incomplete bone marrow recovery (CRi): fulfill all the criteria for CR but have persistent anemia, thrombocytopenia or neutropenia apparently unrelated to disease activity but related to drug toxicity; Partial Remission (PR): ≥ 50% decrease in the peripheral blood lymphocytes from baseline, &gt; 50% reduction in the sum products of up to 6 lymph nodes, &gt; 50% reduction in hepatomegaly and/or neutrophils &gt; 1.5 x109/L, platelets &gt; 100 x109/L, hemoglobin &gt; 110 g/L; Stable Disease: Not CR, PR or PD (equivalent to nonresponse); Progressive Disease: Lymphadenopathy, or appearance of any new lesion/organomegaly, &gt; 50% increase in the size of the liver and/or spleen, &gt; 50% increase in the absolute number of circulating lymphocytes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression Free Survival, Overall Survival</measure>
    <time_frame>36 months</time_frame>
    <description>Progression Free Survival (PFS) is defined as the length of time between the date of first dose of study treatment (GSK2110183) and the earliest date of disease progression or death due to any cause.
Overall survival is defined as the length of time between the date of first dose of study treatment (GSK2110183) and death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Duration of Response</measure>
    <time_frame>36 months</time_frame>
    <description>Duration of Response (DOR) is defined, for the subset of patients with a CR or PR, as the time from first documented evidence of CR or PR until first documented disease progression or death due to any cause. Duration of response will be summarized descriptively using Kaplan-Meier medians and quartiles.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <arm_group>
    <arm_group_label>Ofatumumab with GSK2110183</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofatumumab with GSK2110183</intervention_name>
    <description>GSK2110183 125mg OD continuously
Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses</description>
    <arm_group_label>Ofatumumab with GSK2110183</arm_group_label>
    <other_name>Arzerra and GSK2110183</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must fulfill all of the following criteria to be eligible for admission to
             the study:

               -  A confirmed diagnosis of B-cell CLL by IWCLL 2008 criteria (Appendix 1)

               -  Patients must have evidence of disease progression as evidenced by rapid doubling
                  of peripheral lymphocyte count, progressive lymphadenopathy or
                  hepatosplenomegaly, worsening anemia or thrombocytopenia, or progressive
                  constitutional symptoms [including fatigue, weight loss, night sweats, fever
                  (without infection)]

               -  Must be relapsed or refractory to at least one prior fludarabine-containing
                  regimen (no maximum number of prior regimens).

               -  Age &gt; 18 years.

               -  ECOG performance status of 0, 1 or 2 (Appendix 3)

               -  Signed the Informed Consent form

               -  Life expectancy of ≥ 6 months

               -  Able to swallow and retain oral medication

               -  Normal HbA1C ≤ 0.07

               -  Fasting blood sugar &lt; 7mmol/L

        Exclusion Criteria:

          -  Subjects meeting any of the following criteria are excluded from this study:

               -  CLL therapy, including stem cell transplantation, within 4 weeks of study
                  initiation. Corticosteroids alone may be administered up to seven days prior to
                  the first dose of study drug.

               -  Treatment with any known non-marketed drug substance or experimental therapy
                  within 5 terminal half lives or 4 weeks prior to enrollment, whichever is longer,
                  or currently participating in any other interventional clinical study

               -  Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months
                  prior to start of therapy

               -  Known hypersensitivity to ofatumumab, GSK2110183, or any components therein.

               -  Anticoagulants are permitted only if the subject meets PTT and INR entry criteria
                  (INR and PTT ≤ 1.5 times upper normal limit). Their use must be monitored in
                  accordance with local institutional practice.

               -  Current use of any anti-platelet agent (e.g. dipyridamole, clopidogrel) other
                  than aspirin (81mg daily).

               -  Current use of a prohibited medication based on potential drug-drug interaction -
                  a complete list is found in Appendix 1

               -  Known CNS involvement with CLL

               -  Transformation to aggressive B-cell malignancy (e.g. large B-cell lymphoma,
                  Richter's syndrome, prolymphocytic leukemia [PLL])

               -  &quot;Active&quot; autoimmune disease - prior history of autoimmune hemolysis (DAT positive
                  or negative) or immune thrombocytopenia without current active autoimmune disease
                  is allowed

               -  Subjects who have current active hepatic or biliary disease (with exception of
                  patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or
                  stable non-hepatitis B or C chronic liver disease per investigator assessment -
                  please see below for Hepatitis B and C criteria)

               -  Previously diagnosed diabetes mellitus (Type 1 or 2)

               -  Other past or current malignancy. Subjects who have been free of malignancy for
                  at least 5 years, or have a history of completely resected non-melanoma skin
                  cancer, or successfully treated in situ carcinoma are eligible.

               -  Chronic or current infectious disease requiring systemic antibiotics, antifungal,
                  or antiviral treatment such as, but not limited to, chronic renal infection,
                  chronic chest infection with bronchiectasis, and tuberculosis.

               -  Any medical condition that would require long-term use (&gt; 1 month) of systemic
                  corticosteroids during study treatment (excludes topical or inhaled
                  corticosteroid use)

               -  History of significant cerebrovascular disease in the past 6 months or ongoing
                  event with active symptoms or sequelae

               -  QTc ≥ 470 msec on screening ECG

               -  Clinically significant cardiac disease including unstable angina, acute
                  myocardial infarction within six months prior to study entry, congestive heart
                  failure (NYHA III-IV), and arrhythmia unless controlled by therapy, with the
                  exception of extra systoles or minor conduction abnormalities.

               -  Significant concurrent, uncontrolled medical condition including, but not limited
                  to, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological,
                  cerebral or psychiatric disease which in the opinion of the investigator may
                  represent a risk for the patient.

               -  Any major surgery within the prior 4 weeks.

               -  Known HIV positive

               -  Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In
                  addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status),
                  a HB DNA test will be performed and if positive the subject will be excluded.

               -  Positive serology for hepatitis C (HC) defined as a positive test for HCAb, in
                  which case reflexively perform a HC RIBA immunoblot assay on the same sample to
                  confirm the result

               -  Screening laboratory values: platelets ≤ 30 x 109/L,neutrophils ≤ 0.7 x
                  109/L,creatinine ≥ 2.0 times upper normal limit, total bilirubin ≥ 1.5 times
                  upper normal limit (unless due to a known history of Gilbert's disease), ALT ≥
                  2.5 times upper normal limit, alkaline phosphatase ≥ 2.5 times upper normal
                  limit, INR and PTT ≤ 1.5 times upper normal limit

               -  Pregnant or lactating women. Women of childbearing potential must have a negative
                  pregnancy test at screening.

               -  Women of childbearing potential, including women whose last menstrual period was
                  less than one year prior to screening, unable or unwilling to use adequate
                  contraception from study start to one year after the last dose of protocol
                  therapy. Adequate contraception is defined as intrauterine device, double barrier
                  method or total abstinence. Oral contraceptives are not adequate due to potential
                  drug-drug interaction.

               -  Male subjects unable or unwilling to use adequate contraception methods from
                  study start to one year after the last dose of protocol therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 9, 2012</study_first_submitted>
  <study_first_submitted_qc>February 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2012</study_first_posted>
  <results_first_submitted>April 21, 2018</results_first_submitted>
  <results_first_submitted_qc>September 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 24, 2019</results_first_posted>
  <last_update_submitted>September 20, 2019</last_update_submitted>
  <last_update_submitted_qc>September 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofatumumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 22, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT01532700/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study enrollment was stopped as of 13 Sep 2016. 28 patients were enrolled. Data analysis is complete and manuscript has been being submitted.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ofatumumab With GSK2110183</title>
          <description>Ofatumumab with GSK2110183: - GSK2110183 125mg OD continuously
- Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ofatumumab With GSK2110183</title>
          <description>Ofatumumab with GSK2110183: - GSK2110183 125mg OD continuously
- Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate, as Per the IWCLL 2008 Response Criteria</title>
        <description>IWCLL Response Criteria 2008-Hallek. Complete response (CR): requires peripheral blood lymphocytes &lt; 4 x 109/L, absence of significant lymphadenopathy (&gt;1.5cm), no organomegaly, normal CBC, bone marrow must be at least normocellular; Complete Remission with incomplete bone marrow recovery (CRi): fulfill all the criteria for CR but have persistent anemia, thrombocytopenia or neutropenia apparently unrelated to disease activity but related to drug toxicity; Partial Remission (PR): ≥ 50% decrease in the peripheral blood lymphocytes from baseline, &gt; 50% reduction in the sum products of up to 6 lymph nodes, &gt; 50% reduction in hepatomegaly and/or neutrophils &gt; 1.5 x109/L, platelets &gt; 100 x109/L, hemoglobin &gt; 110 g/L; Stable Disease: Not CR, PR or PD (equivalent to nonresponse); Progressive Disease: Lymphadenopathy, or appearance of any new lesion/organomegaly, &gt; 50% increase in the size of the liver and/or spleen, &gt; 50% increase in the absolute number of circulating lymphocytes</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab With GSK2110183</title>
            <description>Ofatumumab with GSK2110183: - GSK2110183 125mg OD continuously
- Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate, as Per the IWCLL 2008 Response Criteria</title>
          <description>IWCLL Response Criteria 2008-Hallek. Complete response (CR): requires peripheral blood lymphocytes &lt; 4 x 109/L, absence of significant lymphadenopathy (&gt;1.5cm), no organomegaly, normal CBC, bone marrow must be at least normocellular; Complete Remission with incomplete bone marrow recovery (CRi): fulfill all the criteria for CR but have persistent anemia, thrombocytopenia or neutropenia apparently unrelated to disease activity but related to drug toxicity; Partial Remission (PR): ≥ 50% decrease in the peripheral blood lymphocytes from baseline, &gt; 50% reduction in the sum products of up to 6 lymph nodes, &gt; 50% reduction in hepatomegaly and/or neutrophils &gt; 1.5 x109/L, platelets &gt; 100 x109/L, hemoglobin &gt; 110 g/L; Stable Disease: Not CR, PR or PD (equivalent to nonresponse); Progressive Disease: Lymphadenopathy, or appearance of any new lesion/organomegaly, &gt; 50% increase in the size of the liver and/or spleen, &gt; 50% increase in the absolute number of circulating lymphocytes</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03)</title>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab With GSK2110183</title>
            <description>Ofatumumab with GSK2110183: - GSK2110183 125mg OD continuously
- Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response rate (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory Infections (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung Infections (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory infections (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary tract infection (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia Grade 3-4(%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia Grade 3-4 (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia Grade 3-4 (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion related reactions (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression Free Survival, Overall Survival</title>
        <description>Progression Free Survival (PFS) is defined as the length of time between the date of first dose of study treatment (GSK2110183) and the earliest date of disease progression or death due to any cause.
Overall survival is defined as the length of time between the date of first dose of study treatment (GSK2110183) and death due to any cause.</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab With GSK2110183</title>
            <description>Ofatumumab with GSK2110183: - GSK2110183 125mg OD continuously
- Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression Free Survival, Overall Survival</title>
          <description>Progression Free Survival (PFS) is defined as the length of time between the date of first dose of study treatment (GSK2110183) and the earliest date of disease progression or death due to any cause.
Overall survival is defined as the length of time between the date of first dose of study treatment (GSK2110183) and death due to any cause.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median PFS time (months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="7.7" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year overall survival time (months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.3" lower_limit="76.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year overall survival time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1" lower_limit="46.0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Duration of Response</title>
        <description>Duration of Response (DOR) is defined, for the subset of patients with a CR or PR, as the time from first documented evidence of CR or PR until first documented disease progression or death due to any cause. Duration of response will be summarized descriptively using Kaplan-Meier medians and quartiles.</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab With GSK2110183</title>
            <description>Ofatumumab with GSK2110183: - GSK2110183 125mg OD continuously
- Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Median Duration of Response</title>
          <description>Duration of Response (DOR) is defined, for the subset of patients with a CR or PR, as the time from first documented evidence of CR or PR until first documented disease progression or death due to any cause. Duration of response will be summarized descriptively using Kaplan-Meier medians and quartiles.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="3.2" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Twenty-eight patients were evaluable for toxicity and response from the time of their first dose of afuresertib. Adverse events were graded using NCI Common Toxicity Criteria v4.03 at each visit. Patients were assessed four weeks after study discontinuation. Thereafter, for patients off-study for progressive disease, follow-up documented ongoing/late toxicities and death. For patients off-study with CR, PR, or SD, follow-up was every three months until progression or death.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ofatumumab With GSK2110183</title>
          <description>Ofatumumab with GSK2110183: - GSK2110183 125mg OD continuously
- Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC AE ver. 4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain ?Progressive CLL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of pulmonary origin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Invasive squamous cell carcinoma-malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC AE ver. 4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>leg edema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paresthesias</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Christine Chen</name_or_title>
      <organization>University Health Network</organization>
      <phone>416-946-2827</phone>
      <email>Christine.Chen@uhn.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

